Medical experts recommend evidence-based approaches including caloric restriction, at least 150 minutes of weekly exercise, behavioral interventions, and dietary patterns like Mediterranean or DASH diets
The 8mg dose produces 21.1% average weight loss, only slightly less than 12mg
For example, the FLOW trial demonstrated that GLP-1 medications can slow CKD progression and lower the risk of kidney failure
Month 2 (0.5 mg): Appetite reduction tends to become more noticeable
The SURMOUNT-1 trial showed 19.5% average body weight reduction on 10 mg injectable, and sublingual protocols targeting equivalent exposure aim for the same outcome
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ, Endocrine S